探索具有增强结合亲和力的大麻素,以准扩大的内分泌大麻素系统:阿尔茨海默病治疗的有希望的治疗策略
Gabriela Dumitrita Stanciu1, Daniela-Carmen Ababei1,2, Carmen Solcan3
1Advanced Research and Development Center for Experimental Medicine "Prof. Ostin C. Mungiu"-CEMEX, Grigore T. Popa University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania.
Pharmaceuticals (Basel, Switzerland)
|April 27, 2024
概括
包括Cannabis sativa在内的大麻素受体连接体,改善了小鼠的记忆力和减少了阿尔茨海默氏病 (AD) 病理学. 这表明内分泌大麻素系统 (ECS) 是阿尔茨海默病治疗的有希望的目标.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 病理学 病理学 病理学
背景情况:
- 由于治疗方法有限,阿尔茨海默氏症 (AD) 仍然是一个重大挑战.
- 内分泌大麻素系统 (ECS) 在神经保护,炎症和突触可塑性方面发挥作用.
- 大麻素受体配体显示出调节大脑网络和记忆的潜力.
研究的目的:
- 评估JWH-133和Cannabis sativa提取物对APP/PS1小鼠识别记忆的影响.
- 研究对大脑新陈代谢和内分泌系统的影响.
- 探索阿尔茨海默病的潜在治疗策略.
主要方法:
- 在90天内给APP/PS1小鼠服用JWH-133和Cannabis sativa L. (Cannabixir®).
- 评估识别记忆,类似焦虑的行为和大脑代谢.
- 分析了Aβ斑块负载,天体细胞形态和受体表达 (mTOR,CB2,M1 mAChR).
主要成果:
- 大麻素治疗减少了类似焦虑的行为,并部分恢复了认知缺陷.
- 观察到Aβ斑块数量和大小减少,以及大脑葡萄糖代谢减少.
- 在mTOR,CB2受体表达,星细胞大小和M1mAChR表达中注意到了变化.
结论:
- 扩展性内分泌系统在阿尔茨海默氏症的认知衰退和病理学中起着至关重要的作用.
- 大麻素受体配体在阿尔茨海默病治疗中显示出临床前的疗效.
- 进一步研究基于大麻素的AD治疗方法是有必要的.
相关概念视频
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
187
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
187
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
237
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
237
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
121
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
121
Drug-Receptor Interaction: Agonist
2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K


